Abbott Laboratories is announcing new private insurance coverage for a atypical implantable medical device to amusement neuropathic pain, a stubborn blazon of affliction that can drive patients to abiding opioid use.
The device, accepted today as the Proclaim DRG neurostimulator, was awash by Minnesota’s St. Jude Medical until Abbott acquired the company in January 2017. Abbott had cited St. Jude’s band of neurostimulation devices, including its DRG stimulator, as a key motivation for buying the company and stering its growing medical device therapies.
On Tuesday, insurer Aetna unveiled a national coverage decision that opens up coverage for Abbott’s Proclaim DRG neurostimulator, expanding access to the device for about 22 million bodies in Aetna fully-insured and self-insured plans, Abbott said. The device is additionally covered by Medicare, but other major private insurers are still evaluating it for possible coverage.
Seven Common Myths About Aetna Pa Form | Aetna Pa Form – aetna pa form
| Welcome to be able to my personal weblog, in this moment I will teach you with regards to aetna pa form